SRR35579805
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V2+0.540
- UNFOLDED_PROTEIN_RESPONSE+0.450
- MYC_TARGETS_V1+0.440
- MTORC1_SIGNALING+0.420
- MITOTIC_SPINDLE+0.350
- PROTEIN_SECRETION+0.320
- INTERFERON_GAMMA_RESPONSE+0.300
- GLYCOLYSIS+0.280
Top 10 suppressed
- ANGIOGENESIS-0.360
- UV_RESPONSE_DN-0.270
- P53_PATHWAY-0.220
- APICAL_JUNCTION-0.210
- WNT_BETA_CATENIN_SIGNALING-0.210
- TNFA_SIGNALING_VIA_NFKB-0.200
- COAGULATION-0.190
- NOTCH_SIGNALING-0.190
- INFLAMMATORY_RESPONSE-0.180
- MYOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013495 | — | cohortA1 | 0.879 |
| 2 | TCGA-95-7562-01A-11R-2241-07 | — | cohortA4 | 0.860 |
| 3 | SRR23303750 | — | — | 0.845 |
| 4 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.840 |
| 5 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.834 |
| 6 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.830 |
| 7 | SRR8942934 | — | — | 0.823 |
| 8 | TCGA-05-4415-01A-22R-1858-07 | — | cohortA4 | 0.821 |
| 9 | MNG358 | — | — | 0.820 |
| 10 | SRR35579804 | — | C | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |